Holgate, S T <br/><br/>
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.  [electronic resource] 

 -  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology  Apr 2004 
 - 632-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0954-7894 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2222.2004.1916.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Androstadienes--administration & dosage<br/>Anti-Asthmatic Agents--adverse effects<br/>Antibodies, Anti-Idiotypic--adverse effects<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Asthma--drug therapy<br/>Bronchodilator Agents--administration & dosage<br/>Child<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Fluticasone<br/>Humans<br/>Immunoglobulin E--immunology<br/>Male<br/>Middle Aged<br/>Omalizumab<br/>Quality of Life<br/>Treatment Outcome